

PARK CITY, UTAH • JANUARY 3-5, 2019



SUPPORT PROSPECTUS

2019 NASH-TAG

THERAPEUTIC AGENTS FOR NON-ALCOHOLIC
STEATOHEPATITIS AND FIBROSIS



TABLE OF CONTENTS

- 4 Executive Summary / Course Directors
- 5 Scientific Advisory Board Committee
- 6 Agenda
- 7 2019 NASH-TAG Support Opportunities and Important Deadlines
- 8 2019 NASH-TAG Conference Sponsorship Opportunities
- 9 2019 NASH-TAG Exhibit/Sponsor Information Form
- 10 Exhibitor Registration Instructions



EXECUTIVE SUMMARY

We are proud to announce that the 2019 NASH/TAG Conference, our third annual conference, will be held on Thursday, January 3-5, 2019 in Park City, UT. The conference will provide attendees with an opportunity to learn from the leading researchers in NASH and liver fibrosis about innovative science and to engage in interactive discussions and share insight with others on multiple topics related to advances in the diagnosis and management of patients with NASH/NAFLD.

The NASH-TAG conference's primary objective is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with NASH/NAFLD. The conference brings together clinicians, academia, and the pharmaceutical industry to discuss identification of the appropriate patient populations, trial designs, and therapeutic endpoints, as well as the potential benefits these agents can have on patients with NASH. We believe the success of this conference is accomplished by delivering a focused scientific educational update that highlights the most clinically-relevant advances in NASH, which include the future directions in diagnostic procedures and the challenges in drug discovery and development for both NASH and liver fibrosis.

The Scientific Advisory Council of NASH-TAG is an internationally renowned group of academic researchers who help in providing comprehensive strategic planning and guidance for the educational program. These renowned experts will assist in the development of the educational content and will serve as faculty at the conference. They will address the latest clinical trial results, design updates, new pharmacological updates, and the pharmacoeconomic benefit of future treatment to the healthcare system. In addition, the faculty will focus on epidemiology, comorbidities associated with this disease, and the impact of NASH/NAFLD (natural history).

The 2018 NASH-TAG Conference surpassed all of our expectations:

Over 200 attendees

100% conference satisfaction rate from those who responded to our post-survey

Over 94% of respondents would recommend this conference to others and *plan to attend the 2019 meeting*

97% rated the presentations as excellent/outstanding

COURSE DIRECTORS



Michael Charlton, MBBS, MD

Professor of Medicine
University of Chicago
Chicago, IL



Stephen Harrison, MD, FAASLD

Visiting Professor of Hepatology,
Radcliffe Department of Medicine,
University of Oxford
San Antonio, TX



Rohit Loomba, MD, MHSc

Professor of Medicine and Vice Chief,
Division of Gastroenterology
Adjunct Professor, Epidemiology and Public Health
University of California, San Diego
San Diego, CA



Vlad Ratziu, MD

Professor of Hepatology
Hôpital Pitié Salpêtrière, Institute of
Cardiometabolism and Nutrition and Université
Paris, France

SCIENTIFIC ADVISORY BOARD COMMITTEE

Manal Abdelmalek, MD

Duke University
Durham, NC

Quentin Anstee, MD

Newcastle University
Newcastle-Upon-Tyne,
United Kingdom

Kenneth Cusi, MD, FACP, FACE

University of Florida
Gainesville, FL

Anna-Mae Diehl, MD

Duke University
Durham, NC

Stephen H. Caldwell, MD

University of Virginia
Charlottesville, VA

Scott Friedman, MD

Mount Sinai Hospital
New York, NY

Samuel Klein, MD

Washington University
School of Medicine
St. Louis, MO

Yuri Popov, MD, PhD

Harvard Medical School
Boston, MA

Mary Rinella, MD

Northwestern University
Feinberg School of Medicine
Chicago, IL

Arun J. Sanyal, MD

Virginia Commonwealth University
Medical Center
Richmond, VA

Detlef Schuppan

Mainz University Medical Center
Mainz, Germany

Bart Staels, PhD

University of Lille Nord de France
Lille, France

Frank Tacke, MD, PhD

University Hospital Aachen
Aachen, Germany

Brent A. Tetri, MD

Saint Louis University Liver Center
St. Louis, MO

Vincent Wong, MD

The Chinese University of Hong Kong
Hong Kong, China

Hannele Yki-Jarvinen, MD, PhD

University of Helsinki
Helsinki, Finland

Zobair Younossi, MD

Inova Health System
Falls Church, VA

For an updated list of faculty/speakers, please visit our website:

WWW.NASH-TAG.ORG

Conference management services provided by:

Focus Medical Communications

PROPOSED AGENDA*

THURSDAY, JANUARY 3, 2019

18:00 – 21:00 Welcome Reception

FRIDAY, JANUARY 4, 2019

6:45 – 7:30 Breakfast

7:30 – 8:00 The Year 2018 in Review

SESSION 1: LATEST CLINICAL TRIAL RESULTS

Moderators: TBD

8:00 – 8:30 MGL 3196

8:30 – 9:00 Aramchol

9:00 – 9:30 NGM 282

9:30 – 10:00 GS 9674 FXR

10:00 – 10:20 Break – Exhibit Hall/Poster Viewing

SESSION 2: THE LIVER AND ITS METABOLIC CONDITIONING

Moderators: TBD

10:20 – 10:40 AcetylCoA carboxylase activity and metabolic, inflammatory and hepatic consequences: Prospects for NASH Therapy

10:40 – 11:00 Current status on pharmacological options to weight loss agents

11:00 – 11:45 Free Paper Session – 3 Oral Presentations

11:45 – 16:00 Free Time

SESSION 3: EXPERIMENTAL SESSION

Moderators: TBD

16:00 – 16:30 Selective PPAR modulators – Hype or Hope?

16:30 – 17:00 Extracellular Vesicles as mediators of inflammation

**Detailed agenda and presenting faculty to be finalized in fall of 2018*

PROPOSED AGENDA* (CONT.)

17:00 – 17:30	Signals from preclinical models and success of NASH trials
17:30 – 18:00	3D Tissue modeling and precision cut liver slices: Will they help drug testing for NASH?
18:00 – 18:20	Break – Exhibit Hall

FINDING THE NASH PATIENTS: CASE FOR & AGAINST SCREENING FOR NASH

18:20 – 18:30	The case against screening for NASH
18:30 – 18:40	The case in favor of screening for NASH

NASH DRUGS REIMBURSEMENT: PRESENTATIONS & PANEL DISCUSSION

Moderators: TBD

TBA	Barriers to overcome for reimbursement of NASH drugs
TBA	Lessons learned from CV and diabetes trials
TBA	European perspective on reimbursement policies: Market specifics of Germany, UK, and France

SATURDAY, JANUARY 5, 2019

6:45 – 7:30	Breakfast
-------------	-----------

SESSION 1: REFINING CLINICAL TRIAL DESIGN

Moderators: TBD

7:30 – 8:00	Maximizing efficacy and minimizing placebo response
8:00 – 8:30	Challenges in conducting trials in East Asia, India, and Japan
8:30 – 9:00	Current and future trends in hepatic MRI using a background of cardiac MRI development
9:00 – 9:30	Assessing DILI in NASH trials
9:30 – 10:00	Genetic testing: Any use for sub phenotyping or risk stratification in clinical trials?
10:00 – 10:20	Break – Exhibit Hall/Poster Viewing

**Detailed agenda and presenting faculty to be finalized in fall of 2018*

PROPOSED AGENDA* (CONT.)

10:20 – 10:40	Understanding the methods of and need for CV risk assessment
10:40 – 11:00	Second Harmonic Generation fully quantitative histopathology assessment for NASH
11:00 – 11:45	Free Paper Session – 3 Oral Presentations
11:45 – 16:00	Free Time

SESSION 2: NEW PHARMACOLOGICAL TARGETS

Moderators: TBD

16:00 – 16:20	GLP-1 – Semaglutide
16:20 – 16:40	GLP-1R Glucan receptor agonists MEDI 0382
16:40 – 17:00	Novel FGF21 Constructs
17:00 – 17:20	The continuous search for antifibrotic agents
17:20 – 17:40	Integrin antagonism as an Antifibrotic Therapy
17:40 – 18:00	GPR40 and 84G Cell coupled receptor modulators, PBI-4050
18:00 – 18:20	SGM-1019 S
18:20 – 18:40	Break – Exhibit Hall

18:40 – 20:10 FREE PAPERS (6 ORAL PRESENTATIONS)

Moderators: TBD

20:10	Closing Remarks
	Adjourn

**Detailed agenda and presenting faculty to be finalized in fall of 2018*

2019 NASH-TAG SUPPORT OPPORTUNITIES AND IMPORTANT DEADLINES

SUPPORT OPPORTUNITIES

The NASH-TAG Conference offers different levels of sponsorship to support the needs of the more than 200 healthcare professionals who will attend the conference.

NASH-TAG CONFERENCE DATES

January 3-5, 2019

The Chateaux Deer Valley
7815 Royal Street East
Park City, Utah 84060
USA

IMPORTANT DEADLINES

Initial Agreement: Supporters showing interest must commit in writing by completing the "Support Opportunities" found on the last page of this prospectus.

Payment: If requested, invoices can be generated on receipt of the fully executed Letter of Agreement with payment due 60 days from the date of the signed Letter of Agreement. Please include a copy of the invoice and/or purchase order with payment.

Checks should be made payable to:
Focus Medical Communications (Tax ID 20-8216514)

Remit payment to:
Focus Medical Communications
Attn: NASH-TAG
7 Century Drive, Suite 104
Parsippany, NJ 07054

SPONSORSHIP OPPORTUNITIES

The NASH-TAG Conference has designed a comprehensive and multi-tiered corporate sponsorship program that provides substantial benefits at every level. We are excited to announce a new annual corporate sponsorship package for the Diamond, Platinum, and Gold levels. These packages are designed for companies and organizations interested in supporting NASH-TAG on an annual basis. As a corporate sponsor, your company will be listed as the main contributor on the NASH-TAG website.

DIAMOND: \$75,000

At the NASH-TAG Conference:

- A company-sponsored symposium/industry forum
- Eight (8) conference registrations
- Networking Reception Sponsor
- 12-foot conference exhibit*
- Conference Premier App Sponsor
- Conference Bag Sponsor with company logo
- Acknowledgment as a Diamond Sponsor on individual conference websites and all conference materials

PLATINUM: \$50,000

At the NASH-TAG Conference:

- Six (6) conference registrations
- Networking Reception Sponsor
- 12-foot conference exhibit*
- Conference Bag Sponsor with company logo
- Two (2) conference app sponsorships
- Acknowledgment as a Platinum Sponsor on individual conference websites and all conference materials

GOLD: \$25,000

At the NASH-TAG Conference:

- Three (3) conference registrations
- Networking Reception Sponsor
- 6-foot conference exhibit*
- Two (2) conference app sponsorships
- Conference Bag Sponsor with company logo
- Acknowledgment as a Gold Sponsor on individual conference websites and all conference materials

CONFERENCE SPONSOR: \$10,000

At the NASH-TAG Conference:

- 6-foot highly visible exhibit space
- Acknowledgment as a Conference Sponsor on individual conference websites and all conference materials

INDUSTRY SPONSORED SYMPOSIA

Industry-sponsored symposia/industry forum is available with the Diamond package. The programs can be held during non-conference hours.

ANICILLARY MEETING OPPORTUNITIES:

Conference Mobile App –

New App Branding Opportunities for 2019!

PREMIER APP SPONSOR*: \$7,500

Includes:

- Two (2) banner ads featured on the main screen of the app to ensure maximum visibility
- Expanded company profile listing on the sponsor section of the app; sponsor can include photos, brochures, and other marketing materials
- Two (2) push notifications
- Report including data on impression and click-through rates

BANNER AD*: \$5,000

Includes:

- A banner ad featured on the main screen of the app to ensure maximum visibility

PUSH NOTIFICATION*: \$3,000

Includes:

- A push notification will be sent to all conference app users; alerts pop up prominently on each attendee's device

To discuss conference support opportunities further, please contact:

Pablo Gabella

Sr. Director, Business Development
Focus Medical Communications

Tel: 714-869-2769

pgabella@focusmeded.com

2019 NASH-TAG EXHIBIT

SPONSOR INFORMATION FORM

Company Name: _____

Contact: _____

Address: _____

City: _____ State: _____ Zip: _____

Phone: _____ Fax: _____

Email: _____

Authorized Signature: _____ Date: _____

Print Name: _____

PLEASE CHECK LEVEL OF SPONSORSHIP:

☐ Diamond Sponsor – \$75,000

☐ Platinum Sponsor – \$50,000

☐ Gold Sponsor – \$25,000

☐ Conference Sponsor – \$10,000

☐ Premier App Sponsor – \$7,500

☐ Banner Ad – \$5,000

☐ Push Notification – \$3,000

Checks should be made payable to:
Focus Medical Communications
(Tax ID 20-8216514)

Remit payment to:
Focus Medical Communications
Attn: NASH-TAG
7 Century Drive, Suite 104
Parsippany, NJ 07054

EXHIBITOR REGISTRATION INSTRUCTIONS

Your exhibit space is contingent on receiving full payment. All additional requests (e.g., power source, internet access) will be handled between the exhibitor and the hotel. The costs will be directly charged to the exhibitor.

EXHIBIT SPACE SELECTION

The NASH-TAG conference planners will assign the exhibit location in the expo area. Please indicate on your registration form if there are any special circumstances regarding your display.

CANCELLATION POLICY

Requests for cancellation of exhibit space and refunds will be honored only until 14 days prior to the conference start date. A 100% refund less any handling fees will be extended for any cancellations made by that date.

LIABILITY

The EXHIBITOR agrees to protect, save, defend, and keep the conference hotel, NASH-TAG, their agents, and their guests, forever harmless from any damages or charges imposed by the negligence of the exhibitor and/or any loss, cost, damage, liability or expense that arises from the EXHIBITOR'S occupancy and/or use of the exhibit premises.

INSURANCE FOR EXHIBIT ITEMS

The EXHIBITOR is responsible for providing their own insurance on loss of materials. NASH-TAG does not have any insurance. With your signature, you accept the general terms and conditions as stated in the above form.

Signature: _____ Date: _____

Print Name: _____



For more information, please visit:

WWW.NASH-TAG.ORG

Follow Us on Twitter!

@NashTagConf